



Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

May 21, 2021

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--May 21, 2021-- Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTN), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company's Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.

The presentation will be made available for the duration of conference.

Details for the ASCO presentation are as follows:

Session Title: Poster Session: Genitourinary Cancer – Prostate, Testicular and Penile

Title: PSMA-targeted imaging with ¹⁸F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval
Abstract No: 5023

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow[®] serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY[®] Vial for (Perflutren Lipid Microsphere) Injectable Suspension; Technelife[®] (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA[®] for the treatment of certain rare neuroendocrine tumors; and RELISTOR[®] for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, please visit www.lantheus.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210521005043/en/): <https://www.businesswire.com/news/home/20210521005043/en/>

Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Director, Corporate Communications
646-975-2533
media@lantheus.com

Source: Lantheus Holdings, Inc.